Nasal glucagon: A new hope for severe hypoglycemia in type 1 diabetes

Until now, injectable glucagon was the only available treatment used in the management of severe hypoglycemia wherein glucagon had to be prepared in several steps before administration. This method of delivery of injectable glucagon being cumbersome and unappealing for wide majority of the patients had led to a search for an alternative route of drug delivery. nasal glucagon (NG) now serves an efficient, safe, easy-to-administer, and a favorable substitute to glucagon injections. This ready to use device stand in clear contrast to overcome the limitations associated with the currently available glucagon preparations has emerged a key advancement in the management of severe hypoglycemia in adolescents and children with type 1 diabetes. NG is now being developed and studied in other countries as well to meet the unmet need for an easy and convenient glucagon administration. This review covers the basic information of nasal glucagon, trials on nasal glucagon in children and adults and its potential uses, limitations, and future scope in practice.

Keywords

Cumbersome - hypoglycemia - injectable glucagon - nasal glucagon - management

Financial support and sponsorship

Nil.

Publication History

Received: 09 May 2020

Accepted: 03 August 2020

Article published online:
06 July 2022

• References

• 1 Centers for Disease Control and Prevention (CDC). National Diabetes fact Sheet: National Estimates, General Information on Diabetes, Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
• 2 MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993;10:238-45.
• 3 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
• 4 The United Kingdom Prospective Diabetes Study Research Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
• 5 Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop PH. The consequences of failure to achieve targets of guidelines for prevention and treatment of diabetic complications in patients with type 1 diabetes. Acta Diabetol 2015;52:31-8. doi: 10.1007/s00592-014-0595-x.
• 6 Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: An underutilized therapeutic approach. Diabetes Metab Syndr Obes 2011;4:337-46.
• 7 Allicar MP, Megas F, Houzard S, Baroux A, Le Thai F, Augendre-Ferrante B. Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 2000;29:657-61.
• 8 International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American diabetes Association and the European Association for the study of diabetes. Diabetes Care 2017;40:155-7.
• 9 Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-48.
• 10 DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23:857-66.
• 11 Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, et al. National estimates of insulin related hypoglycemi and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014;174:678-86.
• 12 Koster I, Huppertz E, Hauner H, Schubert I. Direct costs of diabetes mellitus in GermanyCoDiM 20002007. Exp Clin Endocrinol Diabetes 2011;119:377-85.
• 13 Holstein A, Patzer OM, Machalke K, Holstein JD, Stumvoll M, Kovacs P. Substantial increase in incidence of severe hypoglycemia between 1997–2000 and 2007–2010: A German longitudinal population-based study. Diabetes Care 2012;35:972-5.
• 14 Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12.
• 15 UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7.
• 16 Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 2003;26:1176-80.
• 17 Merlotti C, Morabito A, Ceriani V, Pontiroli AE. Prevention of type 2 diabetes in obese at-risk subjects: A systematic review and meta-analysis. Acta Diabetol 2014;51:853-63.
• 18 Clarke WL, Gonder-Frederick A, Snyder AL, Cox DJ. Maternal fear of hypoglycaemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998;11:189-94.
• 19 Patton SR, Dolan LM, Henry R, Powers SW. Parental fear of hypoglycaemia: Young children treated with continuous subcutaneous insulin infusion. Pediatr Diabetes 2007;8:362-8.
• 20 Cryer P. Hypoglycaemia in Diabetes: Pathophysiology, Prevalence and Prevention. 2[nd] ed.. Alexandria, VA, USA: American Diabetes Association; 2012.
• 21 Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61.
• 22 American Diabetes Association. Standards of medical care in diabetesdiabetes2013. Diabetes Care 2013;36 Suppl 1:S11-66.
• 23 Guettier JM, Gorden P. Hypoglycemia. Endocrinol Metab Clin North Am 2006;35:753-66.
• 24 Kearney T, Dang C. Diabetic and endocrine emergencies. Postgrad Med J 2007;83:79-86.
• 25 Barret KE, Barman SM. Endocrine functions of the pancreas and regulation of carbohydrate metabolism. Ganong's Review of Medical Physiology. 23[rd] ed.. New York: McGraw-Hill; 2010. p. 315-36.
• 26 Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 1997;273:488-96.
• 27 Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011;13 Suppl 1:118-25.
• 28 Lund A, Knop FK. Extrapancreatic glucagon: Present status. Diabetes Res Clin Pract 2019;147:19-28.
• 29 Hayashi Y, Seino Y. Regulation of amino acid metabolism and α-cell proliferation by glucagon. J Diabetes Investig 2018;9:464-72.
• 30 Elrick H, Witten TA, Arai Y. Glucagon treatment of insulin reactions. N Engl J Med 1958;258:476-80.
• 31 Vukmir RB, Paris PM, Yealy DM. Glucagon: Pre-hospital therapy for hypoglycemia. Ann Emerg Med 1991;20:375-9.
• 32 Muhlhauser I, Koch J, Berger M. Pharmacokinetics and bioavailability of injected glucagon: Differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care 1985;8:39-42.
• 33 Yanai O, Pilpel D, Harman I, Elitzur-Leiberman E, Phillip M. IDDM patients' opinions on the use of Glucagon Emergency Kit in severe episodes of hypoglycaemia. Pract Diabetes Int 1997;14:40-2.
• 34 .Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration-underevaluated and undertaught. Pract Diabetes Int 2001;18:22-5.
• 35 Yale J, Dulude H, Egeth M, Piche C, Lafontaine M, Carballo D, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycaemia rescue: A simulation study. Diab Tech Ther 2017;19:423-32.
• 36 Pedersen JS. The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol 2010;4:1357-67.
• 37 Frequency of Carrying Glucagon [Internet], 2015. Glu poll. https://myglu.org/polls/1303. [Last accessed on 2015 Dec 16].
• 38 Pontiroli AE, Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J (Clin Res Ed) 1983;287:462-3.
• 39 Pontiroli AE, Alberetto M, Pozza G. Metabolic effects of intranasally administered glucagon: Comparison with intramuscular and intravenous injection. Acta Diabetol Lat 1985;22:103-10.
• 40 Pontiroli AE, Alberetto M, Calderara A, Pajetta E, Pozza G. Nasal administration of glucagon and human calcitonin to healthy subjects: A comparison of powders and spray solutions and of different enhancing agents. Eur J Clin Pharmacol 1989;37:427-30.
• 41 Slama G, Alamowitch C, Desplanque N, Letanoux M, Zirinis P. A new non-invasive method for treating insulin-reaction: Intranasal lyophylized glucagon. Diabetologia 1990;33:671-4.
• 42 Teshima D, Yamauchi A, Makino K, Kataoka Y, Arita Y, Nawata H, et al. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm 2002;233:61-6.
• 43 Rosenfalck AM, Bendtson I, Jorgensen S, Binder C. Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulindependent) diabetic patients. Diabetes Res Clin Pract 1992;17:43-50.
• 44 Wolfe T, Barton E. Nasal drug delivery in EMS: Reducing needlestick risk. JEMS 2003;28:52-63.
• 45 Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24.
• 46 Boido A, Ceriani V, Pontiroli AE. Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: A systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol 2015;52:405-12.
• 47 Baqsimi (Glucagon Nasal Powder) [Prescribing Information]. Indianapolis, IN: Lilly USA; 2019.
• 48 Pontiroli AE. Intranasal glucagon: A promising approach for treatment of severe hypoglycemia. J Diabetes Sci Technol 2015;9:38-43.
• 49 Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study. Diabetes Care 2016;39:264-70.
• 50 Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, et al. Glucagon nasal powder: A promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care 2016;39:555-62.
• 51 Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, et al. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab 2018;20:646-53.
• 52 Stenninger E, Aman J. Intranasal glucagon treatment relieves hypoglycaemia in children with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993;36:931-5.
• 53 Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes 2018;19:1007-13.
• 54 Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab 2018;20:1316-20.
• 55 Pontiroli AE, Ceriani V. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality? Diabetes Obes Metab 2018;20:1812-6.
• 56 Grant JS, Graven LJ. Intranasal glucagon for severe hypoglycemia. Home Healthc Now 2017;35:114-5.
• 57 Stahel P, Lee SJ, Sud SK, Floh A, Dash S. Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults. Diab Obes Metab 2019;21:1357-64.
• 58 Mohnike K, Blankenstein O, Pfuetzner A, Potzsch S, Schober E, Steiner S, et al. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 2008;70:59-64.
• 59 Kalra S, Dhingra M, Intranasal Glucagon. J Pak Med Assoc 2019;69:1219-21.
• 60 GlucaGen (Glucagon for Injection) [Prescribing Information]. Plainsboro, NJ: Novo Nordisk; 2018.
• 61 Glucagon for Injection [Prescribing Information]. Indianapolis, IN: Lilly USA; 2018.